RU2001117833A - GRINDING METHOD FOR PRODUCING FINE-GRINDED MEDICAL SUBSTANCES - Google Patents

GRINDING METHOD FOR PRODUCING FINE-GRINDED MEDICAL SUBSTANCES

Info

Publication number
RU2001117833A
RU2001117833A RU2001117833/03A RU2001117833A RU2001117833A RU 2001117833 A RU2001117833 A RU 2001117833A RU 2001117833/03 A RU2001117833/03 A RU 2001117833/03A RU 2001117833 A RU2001117833 A RU 2001117833A RU 2001117833 A RU2001117833 A RU 2001117833A
Authority
RU
Russia
Prior art keywords
crystalline substance
product
less
amorphous phase
grinded
Prior art date
Application number
RU2001117833/03A
Other languages
Russian (ru)
Other versions
RU2234375C2 (en
Inventor
Жан-Рене Отелен
Патрик ХОСЕК
Original Assignee
Авентис Фарма Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9826286.8A external-priority patent/GB9826286D0/en
Application filed by Авентис Фарма Лимитед filed Critical Авентис Фарма Лимитед
Publication of RU2001117833A publication Critical patent/RU2001117833A/en
Application granted granted Critical
Publication of RU2234375C2 publication Critical patent/RU2234375C2/en

Links

Claims (14)

1. Способ получения тонкого высококристалличного вещества, заключающийся в распылительном размоле кристаллического вещества с использованием мельничной среды, включающей гелий, при пониженной температуре.1. A method of obtaining a fine highly crystalline substance, which consists in spray grinding a crystalline substance using a mill medium, including helium, at a reduced temperature. 2. Способ по п.1, где мельничная среда состоит из гелия.2. The method according to claim 1, where the mill medium consists of helium. 3. Способ по п.1 или 2, где температура мельничной среды находится в интервале между -30°С и -120°С.3. The method according to claim 1 or 2, where the temperature of the mill medium is in the range between -30 ° C and -120 ° C. 4. Способ по п.1 или 2, где температура мельничной среды находится в интервале между -50°С и -70°С.4. The method according to claim 1 or 2, where the temperature of the mill medium is in the range between -50 ° C and -70 ° C. 5. Способ по любому из пп.1-4, где кристаллическое вещество включает порошок медикамента.5. The method according to any one of claims 1 to 4, where the crystalline substance comprises a medicament powder. 6. Способ по п.5, где кристаллическое вещество является ацетонидом триамцинолона.6. The method according to claim 5, where the crystalline substance is a triamcinolone acetonide. 7. Способ по любому из пп.1-6, где продукт имеет содержание аморфной фазы менее 5%.7. The method according to any one of claims 1 to 6, where the product has an amorphous phase content of less than 5%. 8. Способ по п.7, где продукт имеет содержание аморфной фазы менее 2%.8. The method according to claim 7, where the product has an amorphous phase content of less than 2%. 9. Способ по п.8, где продукт имеет содержание аморфной фазы менее 1%.9. The method of claim 8, where the product has an amorphous phase content of less than 1%. 10. Способ по любому из пп.1-9, где продукт состоит из порошка медикамента в форме, пригодной для ингаляции.10. The method according to any one of claims 1 to 9, where the product consists of a powder of a medicament in a form suitable for inhalation. 11. Способ по п.10, где продукт имеет средний размер частиц менее 10 микрон.11. The method of claim 10, where the product has an average particle size of less than 10 microns. 12. Кристаллическое вещество, практически не содержащее аморфной фазы, имеющее средний размер частиц порядка 1 микрона.12. A crystalline substance that practically does not contain an amorphous phase, having an average particle size of the order of 1 micron. 13. Кристаллическое вещество по п.12, которое является ацетонидом триамцинолона.13. The crystalline substance according to item 12, which is a triamcinolone acetonide. 14. Кристаллическое вещество по п.12 или 13, которое получено способом по любому из пп.1-11.14. The crystalline substance according to item 12 or 13, which is obtained by the method according to any one of claims 1 to 11.
RU2001117833/03A 1998-12-01 1999-12-01 Method for milling and producing of finely-dispersed medicinal substances RU2234375C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9826286.8 1998-12-01
GBGB9826286.8A GB9826286D0 (en) 1998-12-01 1998-12-01 Process

Publications (2)

Publication Number Publication Date
RU2001117833A true RU2001117833A (en) 2003-06-27
RU2234375C2 RU2234375C2 (en) 2004-08-20

Family

ID=10843362

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001117833/03A RU2234375C2 (en) 1998-12-01 1999-12-01 Method for milling and producing of finely-dispersed medicinal substances

Country Status (25)

Country Link
US (2) US7041318B2 (en)
EP (2) EP1146964B1 (en)
JP (1) JP4592955B2 (en)
KR (1) KR100658010B1 (en)
CN (1) CN1096886C (en)
AT (1) ATE234684T1 (en)
AU (1) AU758212B2 (en)
BR (1) BRPI9915841B8 (en)
CA (1) CA2352779A1 (en)
CZ (2) CZ296782B6 (en)
DE (1) DE69906147T2 (en)
DK (2) DK1338273T3 (en)
ES (2) ES2195668T3 (en)
GB (1) GB9826286D0 (en)
HK (1) HK1037563A1 (en)
HU (1) HU226221B1 (en)
IL (1) IL143345A (en)
MX (1) MXPA01005471A (en)
NO (1) NO324231B1 (en)
NZ (1) NZ512091A (en)
PL (1) PL193799B1 (en)
PT (1) PT1146964E (en)
RU (1) RU2234375C2 (en)
SI (1) SI1146964T1 (en)
WO (1) WO2000032313A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
JO3510B1 (en) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd Use of glycopyrrolate for treating tachycardia
DE102011102614A1 (en) * 2011-05-27 2012-11-29 Roland Nied Method for operating a jet mill and jet mill
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CA2960694C (en) 2014-09-09 2021-05-04 Vectura Limited Formulation comprising glycopyrrolate, method and apparatus
RU2623608C1 (en) * 2016-02-09 2017-06-28 Владимир Никитович Анциферов Method of milling the powder from plastic material
CN109097582B (en) * 2018-08-17 2020-07-03 安阳工学院 Powdery waste treatment system for mechanical engineering
JP7090941B2 (en) * 2018-10-02 2022-06-27 学校法人 名城大学 Inhalation powder, its evaluation method and its use
CN113751171A (en) * 2021-09-14 2021-12-07 威海德尚医中医药科技有限公司 Preparation method of traditional Chinese medicine superfine powder preparation
CN115737610B (en) * 2021-12-13 2024-02-27 苏州欧米尼医药有限公司 Air flow crushing method for tiotropium bromide inhalation powder fog agent and active ingredient thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897010A (en) * 1971-07-02 1975-07-29 Linde Ag Method of and apparatus for the milling of granular materials
DE2133019A1 (en) * 1971-07-02 1973-01-18 Linde Ag METHOD AND DEVICE FOR COLD JET MILLING
GB1481304A (en) * 1974-09-05 1977-07-27 Boc International Ltd Powder forming
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US4767612A (en) * 1987-01-23 1988-08-30 Rorer Pharmaceutical Corporation Triamcinolone acetonide for the treatment of allergic rhinitis
FR2628415A1 (en) * 1988-03-09 1989-09-15 Rhone Poulenc Chimie PROCESS FOR MANUFACTURING SUPERCONDUCTING MATERIALS AND PRODUCTS THUS OBTAINED
ATE111364T1 (en) 1989-05-31 1994-09-15 Fisons Plc MEDICATION AND INHALER DEVICE THEREFOR.
SE9302777D0 (en) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (en) 1991-04-11 1991-04-11 Astra Ab PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES
US5747002A (en) * 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
SE9501384D0 (en) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5682658A (en) 1996-03-04 1997-11-04 Utica Enterprises, Inc. Rotary index table assembly
EP0885065B1 (en) * 1996-03-08 2001-02-21 E.I. Du Pont De Nemours And Company Improved fluid energy mill
SE9700135D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation

Similar Documents

Publication Publication Date Title
RU2001117835A (en) GRINDING METHOD FOR PRODUCING FINE-GRINDED MEDICAL SUBSTANCES
RU2001117833A (en) GRINDING METHOD FOR PRODUCING FINE-GRINDED MEDICAL SUBSTANCES
DE69108142T2 (en) Composition for use in the oral cavity.
TWI237567B (en) Polyol composition useful as tableting aid and the preparation process thereof
CA2182282A1 (en) Process for preparing fine particle pharmaceutical formulations
RU96123761A (en) METHOD FOR PRODUCING POWDER FAT-CONTAINING FOOD PRODUCT
RU96102011A (en) XINAFOAT SALMETEROL WITH ADJUSTABLE PARTICLE SIZE
WO2002066014A3 (en) Cubic liquid crystalline compositions and methods for their preparation
CA2522486A1 (en) Bromide and crystals thereof
EP1338273A3 (en) Crystalline triamcinolone acetonide produced by a milling process
JPH02223537A (en) Method for isolation of ibuprofen for direct making of tablets
CA2175470A1 (en) Novel pharmaceutical composition for the preparation of a stable powder containing an active principle comprising an association of acetylsalicylic acid and metoclopramide
JP2650090B2 (en) Processed salt and its production method
EP1023041A1 (en) Co-ground products for the cosmetic and dermatological use
JP4519420B2 (en) Crystalline cellulose fine powder
CA2413692A1 (en) Method of making particles for use in a pharmaceutical composition
SK54593A3 (en) Benzenedimethanol suitable for micronisation
CA2024863A1 (en) The manufacture of pellets of xanthine derivatives
AU2001284476A1 (en) Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
EP1407665A4 (en) Granulated wettable powder
HK18297A (en) (R)-3-methoxy-4-1-methyl-5-(2-methyl-4,4,4-trifluorobutylcarbamoyl)indol-3-ylmethyl-N-(2-methylsulphonyl) benzamide in crystalline form
JP2004298046A (en) Method for preventing flotation of exocarp of citrus and agent for preventing the same
ES2086966T3 (en) PRELIMINARY PRODUCT FOR MANUFACTURE OF POWDER.
Harshe et al. Rapidly Solidified Aluminum--Copper Flakes and Their Conversion to Powder
CA2378965A1 (en) Topical antiseptic composition